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La Jolla, California; Paris, France; London and Cambridge, United Kingdom; and Amsterdam, the Netherlands
Objectives This study sought to assess whether oxidation-specific biomarkers are associated with an increased risk of coro-
nary artery disease (CAD) events.
Background The relationship of a panel of oxidative biomarkers and lipoprotein(a) [Lp(a)] to CAD risk is not fully determined.
Methods A prospective case-control study nested in the EPIC (European Prospective Investigation of Cancer)-Norfolk cohort of
45- to 79-year-old apparently healthy men and women followed for 6 years was designed. Cases consisted of partic-
ipants in whom fatal or nonfatal CAD developed, matched by sex, age, and enrollment time with controls without
CAD. Baseline levels of oxidized phospholipids on apolipoprotein B-100 particles and Lp(a) were measured in 763
cases and 1,397 controls. Their relationship to secretory phospholipase A2 type IIA mass and activity, myeloperoxi-
dase mass, and lipoprotein-associated phospholipase A2 activity and association with CAD events were determined.
Results After adjusting for age, smoking, diabetes, low- and high-density lipoprotein cholesterol, and systolic blood pressure,
the highest tertiles of oxidized phospholipids on apolipoprotein B-100 particles and Lp(a) were associated with a sig-
nificantly higher risk of CAD events (odds ratios: 1.67 and 1.64, respectively; p  0.001) compared with the lowest
tertiles. The odds ratio of CAD events associated with the highest tertiles of oxidized phospholipids on apolipoprotein
B-100 particles or Lp(a) was significantly potentiated (approximately doubled) by the highest tertiles of secretory
phospholipase A2 activity and mass but less so for myeloperoxidase and lipoprotein-associated phospholipase A2 ac-
tivity. The odds ratios for fatal CAD were higher than for the combined end point. After taking into account the Fra-
mingham Risk Score, c-index values progressively increased when oxidative biomarkers were added to the model.
Conclusions This EPIC-Norfolk study links pathophysiologically related oxidation-specific biomarkers and Lp(a) with CAD
events. Oxidation-specific biomarkers provide cumulative predictive value when added to traditional cardiovascu-
lar risk factors. (J Am Coll Cardiol 2010;56:946–55) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.048i
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Ahe clinical application of biomarkers to predict cardiovas-
ular disease (CVD) is increasing rapidly. The ability of
iomarkers to define the presence of CVD, predict new
VD events, and reflect the benefit of therapeutic interven-
ions is contingent on their ability to provide easily mea-
ured and noninvasive parameters that will generate insights
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nion, Stroke Association, British Heart Foundation, Department of Health, Food 2nto CVD pathophysiology. Such insights will afford clini-
ians a refined approach to optimally diagnose, treat, and
onitor patients at high risk of atherothrombotic events.
In this regard, several novel oxidative biomarkers have been
roposed to be of value in predicting future CVD events.
ipoprotein-associated phospholipase A2 (Lp-PLA2) (1) and
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September 14, 2010:946–55 Oxidation-Specific Biomarkers and Coronary Eventsecretory phospholipase A2 (sPLA2) (2,3) are enzymes that
eact with oxidized phospholipids (OxPLs) and cleave the
xidized fatty acid side chain at the sn2 position of OxPL to
enerate lysophosphatidylcholine and an oxidized free fatty
cid. Myeloperoxidase (4) is an enzyme derived from activated
eukocytes that mediates the generation of oxidized low-
ensity lipoprotein (LDL) and high-density lipoprotein by
sing hydrogen peroxide and other oxidants as substrates.
ased on a series of clinical studies showing enhanced predic-
ive value, Lp-PLA2 mass (5) and myeloperoxidase mass (4)
ave been approved for clinical use in assessing CVD risk.
Measures of oxidized lipoproteins are also being applied
o a wide variety of CVD studies in assessing risk prediction
6–8). OxPL on apolipoprotein B-100 (OxPL/apoB) lev-
ls, measured with monoclonal antibody E06, are elevated
n patients with multiple manifestations of anatomic and
ymptomatic CVD (9–13). OxPL/apoB levels are indepen-
ent of all known demographic and biochemical risk factors,
xcept for lipoprotein(a) [Lp(a)]. Remarkably, E06-
etectable OxPLs are preferentially carried by Lp(a) as op-
osed to other lipoproteins (14,15). Lp(a) is composed of
polipoprotein B-100 and apolipoprotein(a), and Lp(a) plasma
evels are primarily mediated by the apolipoprotein(a) gene
ocus and generally do not correlate with other risk factors.
lthough OxPLs can be generated by a variety of oxidative
athways, their measurement in the current assay format by
ntibody E06 most closely represents binding of OxPL by
p(a), and therefore OxPL/apoB also reflects the genetic
redisposition of Lp(a) levels. The ability of Lp(a) to bind and
ransport OxPLs may represent a key component of the
therothrombotic risk associated with Lp(a).
Although all these biomarkers may confer additional
alue to clinical risk prediction individually, biomarkers
nvolved in oxidative stress pathways have not been system-
tically evaluated in the same population for their associa-
ion with and prediction of CVD events. In addition, the
ew studies that showed improved risk stratification for
oronary artery disease (CAD) by using multiple biomarkers
id not generally include biomarkers amenable to modifi-
ation by existing medications. In the current study using
he prospectively followed EPIC (European Prospective
nvestigation of Cancer)-Norfolk cohort (16), we hypothe-
ized that elevated baseline levels of OxPL/apoB and Lp(a)
ould be associated with an increased risk of fatal and
onfatal CAD events. Second, we hypothesized that the
isk of CAD conferred by OxPL/apoB or Lp(a) would be
otentiated by several pathophysiologically related but
nique oxidative biomarkers, such as sPLA2 mass and
ctivity, Lp-PLA2 activity, and myeloperoxidase mass.
ethods
tudy population. A nested case-control study among par-
icipants in the EPIC-Norfolk cohort was designed as previ-
usly described (16). Briefly, 25,663 healthy men and women
etween 45 and 79 years of age were recruited from age-sex
egisters of general practices in Norfolk, United Kingdom. The marticipants completed a baseline
uestionnaire survey between 1993
nd 1997, attended a clinic visit,
nd were followed for an average
f 6 years. Individuals who re-
orted a history of heart attack or
troke at the baseline visit were
xcluded. Case ascertainment was
escribed previously. All individ-
als were flagged for death certi-
cation at the United Kingdom
ffice of National Statistics, with
ital status ascertained for the
ntire cohort. In addition, partic-
pants admitted to hospitals were
dentified using their National
ealth Service number by data link-
ge with the East Norfolk Health
uthority database, which identi-
es all hospital contacts through-
ut England and Wales for Nor-
olk residents. Participants were
dentified as having CAD during
ollow-up if they had a hospital admission and/or died with
AD as the underlying cause. CAD was defined as codes 410
o 414 according to the International Classification of Diseases
th Revision. These codes encompass the clinical spectrum of
AD such as unstable angina, stable angina, and myocardial
nfarction. Controls were participants who remained free of
AD events during follow-up. Data on noncardiac events
ere not collected. Two controls were matched to each case by
ex, age (within 5 years), and time of enrollment (within 3
onths). The study was approved by the Norwich Health
uthority Ethics Committee, and all participants provided
ritten informed consent.
aboratory and oxidative biomarker measurements. Blood
amples were stored at 80°C at the Clinical School,
niversity of Cambridge. OxPL/apoB content was mea-
ured by chemiluminescent enzyme-linked immunosorbent
ssay, as described previously in detail, using the murine
onoclonal antibody E06, which binds to the phosphocho-
ine head group of oxidized but not native phospholipids
11,17). By design, the OxPL/apoB measurement is inde-
endent of apoB-100 and LDL cholesterol levels, as previ-
usly reported (12). We previously showed that these
iomarkers are stable with prolonged freezing or transport
o processing sites on ice (12,18,19). It should be empha-
ized that the OxPL/apoB assay does not measure the total
xPL present in plasma or OxPL not detected by E06, and
06 does not cross-react with apolipoprotein(a).
Serum sPLA2 activity was measured by a selective fluorometric
ssay by using fluorescent substrate 1-hexadecanoyl-2-(1-
yrenedecanoyl)-sn-glycero-3 phosphomethanol, sodium salt
Interchim, Montlucon, France), as previously described
2,20). The minimum detectable activity was 0.10 nmol/
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
CVD  cardiovascular
disease
FRS  Framingham Risk
Score
LDL  low-density
lipoprotein
Lp(a)  lipoprotein(a)
Lp-PLA2  lipoprotein-
associated phospholipase A2
OR  odds ratio
OxPL  oxidized
phospholipid
OxPL/apoB  oxidized
phospholipids on
apolipoprotein B-100
sPLA2  secretory
phospholipase A2in/ml. sPLA2 type IIA mass was measured as previously
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Oxidation-Specific Biomarkers and Coronary Events September 14, 2010:946–55escribed (2,20). Lp-PLA2 activity was measured in dupli-
ate from ethylenediamine tetraacetic acid plasma stored at
80°C by the trichloroacetic acid precipitation procedure in
6-well plates, as described previously (21).
Lp(a) levels were measured as previously described with
onoclonal antibody LPA4 (10). Myeloperoxidase mass
nd high-sensitivity C-reactive protein were measured as
reviously described (22,23).
tatistical analysis. Baseline characteristics were compared
etween cases and controls taking into account matching
etween groups. Variables with a skewed distribution were
og-transformed before being used as continuous variables
n analyses, but untransformed medians and corresponding
nterquartile ranges are shown in the tables. To determine
elationships of OxPL/apoB and Lp(a) with CVD risk
actors, we calculated mean risk factor levels per tertile. In
ddition, odds ratios (ORs) and corresponding 95% confi-
ence intervals (CIs) as an estimate of the relative risk of
ncident CAD events were calculated using conditional
ogistic regression analysis. The lowest OxPL/apoB and
p(a) tertiles were used as reference category. Analyses took
nto account the matching for sex, age, and enrollment time
nd adjusted for diabetes mellitus, smoking (never, previous,
urrent), systolic blood pressure, and LDL and high-density
ipoprotein cholesterol. Analyses were also performed that
ook into account the matching variables and adjusted for
he Framingham Risk Score (FRS). Analyses were per-
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Contro
n 1,397
Male sex 61.6 (86
Age, yrs 65
Body mass index, kg/m2 26.2
Waist, cm 91
Diabetes mellitus 1.8 (2
Smoking
Current 8.7 (12
Previous 51.0 (71
Never 40.3 (56
Systolic blood pressure, mm Hg 139
Diastolic blood pressure, mm Hg 83
Total cholesterol, mmol/l 6.3
LDL cholesterol, mmol/l 4.1
HDL cholesterol, mmol/l 1.4
Triglycerides, mmol/l 1.6 (1.2–2
Apolipoprotein A-I, mg/dl 162
Apolipoprotein B, mg/dl 127
C-reactive protein, mg/l 1.5 (0.7–3
Myeloperoxidase, pmol/l 520 (338–8
sPLA2 type IIA mass, mg/dl 10.4
sPLA2 activity, nmol/min/ml 4.4
Lp-PLA2 activity, nmol/min/ml 51
OxPL/apoB, RLUs 1,659 (1,121
Lp(a), mg/dl 8.5 (6.4–1
Data are shown as n, % (n), mean  SD, or median (95% confidence
CI  confidence interval; HDL  high-density lipoprotein; LDL  low-density
phospholipase A2; OxPL/apoB  oxidized phospholipids on apolipoprotein B-ormed for men and women separately and in addition for
exes pooled, additionally adjusting for sex. Additional
nalyses were performed according to tertiles of OxPL/
poB, Lp(a), sPLA2 mass and activity, Lp-PLA2 activity,
nd myeloperoxidase mass.
Correlations were computed using Spearman’s rank-
rder method to avoid distributional assumptions, and p 
.001 was considered significant to account for multiple
omparisons. We calculated the area under the receiver-
perator characteristic curve (and corresponding 95% CI)
nd derived both conditional and unconditional c-indexes
or a set logistic regression models with FRS  each
ndividual biomarker and with FRS  cumulative adding of
he biomarkers. Statistical analyses, including the condi-
ional logistic regression analysis, were performed using
PSS software version 12.0.1 (SPSS, Inc., Chicago, Illi-
ois). A value of p  0.05 was considered significant.
esults
tudy population. As expected, cases had a higher occur-
ence of all CVD risk factors measured than controls (Table 1).
n particular, cases had significantly higher levels of OxPL/
poB, Lp(a), sPLA2 mass and activity, and Lp-PLA2 activity
han controls, and there was a strong trend toward higher levels
f myeloperoxidase mass.
pulation
Cases p Value
763
62.6 (478) Matched
65 8 Matched
27.2 3.8 0.001
94 12 0.001
6.0 (46) 0.001
15.3 (117)
51.8 (395) 0.001
32.9 (251)
143 19 0.001
86 12 0.001
6.5 1.2 0.001
4.3 1.1 0.001
1.3 0.4 0.001
1.9 (1.4–2.6) 0.001
155 29 0.001
137 31 0.001
2.2 (1.0–4.9) 0.001
549 (352–869) 0.08
12.4 10.6 0.001
4.8 1.5 0.001
53 16 0.006
) 1,899 (1,243–3,250) 0.001
9.7 (7.0–25.7) 0.001
l).ndy Po
ls
1)
8
3.4
11
5)
1)
3)
3)
18
11
1.2
1.0
0.4
.2)
29
30
.2)
27)
8.3
1.1
16
–2,591
3.6)
interva
lipoprotein; Lp(a)  lipoprotein(a); Lp-PLA2  lipoprotein-associated
100; RLU  relative light unit.
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onfatal CAD events. As an estimate of the relative risk of
atal and nonfatal CAD, ORs and corresponding 95% CIs
ere calculated by tertiles of OxPL/apoB and Lp(a)
Table 2). Analyses took into account the matching of cases
nd controls by age, sex, and enrollment time. Model 1 further
djusted for diabetes, smoking, systolic blood pressure, LDL,
nd high-density lipoprotein cholesterol, and model 2 adjusted
or the FRS. There was a strong relationship between OxPL/
poB and Lp(a) with risk of future CAD. For example, in
odel 1, subjects in the highest tertile of OxPL/apoB had an
R for CAD events of 1.67 (95% CI: 1.32 to 2.12) compared
ith the lowest tertile (p  0.001). Similarly, subjects in the
ighest tertile of Lp(a) had an OR of 1.64 (95% CI: 1.30 to
.08) compared with the lowest tertile (p  0.001). The
ndings using model 2 were comparable to those of model 1,
nd similar results were also obtained for men and women
Table 2). No significant differences were noted in either
odel according to age 65 years or younger versus age older
han 65 years (data not shown).
For the fatal CAD end point alone, in model 1,
ubjects in the highest tertile of OxPL/apoB had an OR
or CAD events of 1.99 (95% CI: 1.25 to 3.18) compared
ith the lowest tertile (p  0.004). Similarly, subjects in
he highest tertile of Lp(a) had an OR of 2.22 (95% CI:
Odds Ratio (95% CI) of CAD by Tertiles of OxPLTable 2 Odds Ratio (95% CI) of CAD by Tert
OxPL/apoB
Tertile 1
<1,150 RLUs 1
Entire cohort
Unadjusted 1.00
Adjusted model 1 1.00
Adjusted model 2 1.00
Men
Unadjusted 1.00
Adjusted model 1 1.00
Adjusted model 2 1.00
Women
Unadjusted 1.00
Adjusted model 1 1.00
Adjusted model 2 1.00
Lp(a)
Tertile 1
<7.25 mg/dl 7
Entire cohort
Unadjusted 1.00
Adjusted model 1 1.00
Adjusted model 2 1.00
Men
Unadjusted 1.00
Adjusted model 1 1.00
Adjusted model 2 1.00
Women
Unadjusted 1.00
Adjusted model 1 1.00
Adjusted model 2 1.00
Model 1 matched for sex, age, and enrollment time and adjusted for dia
matched for sex, age, and enrollment time, and adjusted for Framingham Risk S
CAD  coronary artery disease; other abbreviations as in Table 1..44 to 3.43) compared with the lowest tertile (p 
.001). The findings using model 2 were comparable to
hose of model 1, and similar results were also obtained
or men and women.
elationship of OxPL/apoB and Lp(a) to other oxidative
iomarkers with fatal and nonfatal CAD events. A 3 
tertile analysis was generated to assess the relationships
etween pairs of biomarkers in the association with risk of
uture CAD (Table 3). Subjects in the highest tertiles for
oth OxPL/apoB and sPLA2 activity had a significantly
levated risk of future CAD, with an OR of 3.46 (95% CI:
.22 to 5.42) compared with subjects in the lowest tertiles
Fig. 1A, Table 3). A similar but weaker relationship was
oted for the highest tertiles of OxPL/apoB and sPLA2
ass (OR: 2.39; 95% CI: 1.58 to 3.61). Strong relationships
ere also noted for Lp(a) and sPLA2 mass and activity. For
xample, the OR subjects in the highest tertiles of Lp(a) and
PLA2 activity was 2.97 (95% CI: 1.93 to 4.57) (Fig. 2B,
able 3). The relationship of OxPL/apoB and Lp(a) to fatal
nd nonfatal CAD was also accentuated in the highest
ertiles (OR: 1.77, 95% CI: 1.31 to 2.37) (Fig. 2, Table 3).
For the remaining pairs of biomarkers, the highest ORs
or CAD were generally observed for subjects in the highest
ertile of either sPLA2 activity or sPLA2 mass and the highest
ertiles of myeloperoxidase (Table 3). Notably, the OR was
B and Lp(a)of OxPL/apoB and Lp(a)
rtile 2
2,249 RLUs
Tertile 3
>2,249 RLUs
p Trend
Linearity
.97–1.52) 1.61 (1.29–2.01) 0.001
.04–1.68) 1.67 (1.32–2.12) 0.001
.01–1.60) 1.66 (1.32–2.09) 0.001
.99–1.75) 1.59 (1.20–2.11) 0.001
.05–1.94) 1.65 (1.21–2.24) 0.001
.06–1.92) 1.70 (1.26–2.29) 0.001
.67–1.39) 1.60 (1.12–2.28) 0.009
.70–1.56) 1.67 (1.14–2.44) 0.007
.67–1.41) 1.58 (1.10–2.26) 0.01
rtile 2
1.69 mg/dl
Tertile 3
>11.69 mg/dl
p
Linearity
.90–1.40) 1.69 (1.35–2.11) 0.001
.88–1.43) 1.64 (1.30–2.08) 0.001
.88–1.39) 1.64 (1.31–2.06) 0.001
.93–1.64) 1.78 (1.35–2.34) 0.001
.97–1.80) 1.75 (1.30–2.36) 0.001
.94–1.69) 1.76 (1.32–2.34) 0.001
.74–1.56) 1.62 (1.12–2.35) 0.009
.68–1.51) 1.58 (1.06–2.35) 0.02
.72–1.52) 1.57 (1.08–2.28) 0.02
moking, systolic blood pressure, and LDL and HDL cholesterol. Model 2/apoiles
Te
,150–
1.21 (0
1.32 (1
1.27 (1
1.31 (0
1.43 (1
1.42 (1
0.96 (0
1.05 (0
0.97 (0
Te
.25–1
1.12 (0
1.12 (0
1.11 (0
1.24 (0
1.32 (0
1.26 (0
1.08 (0
1.01 (0
1.05 (0
betes, s
core.
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Oxidation-Specific Biomarkers and Coronary Events September 14, 2010:946–55Odds Ratio (95% CI) for CAD Events According to Tertiles of Selected BiomarkersTable 3 Odds Ratio (95% CI) for CAD Events According to Tertiles of Selected Biomarkers
T1 T2 T3
OxPL/apoB
Lp(a) T1 1.00 1.04 (0.72-1.51) 1.07 (0.58-1.98)
T2 0.95 (0.66–1.35) 1.36 (0.97–1.92) 1.25 (0.74–2.10)
T3 0.89 (0.42–1.90) 1.63 (1.03–2.58) 1.77 (1.31–2.39)
sPLA2 activity T1 1.00 1.26 (0.81–1.98) 1.75 (1.14–2.70)
T2 1.16 (0.74–1.80) 2.10 (1.36–3.25) 2.04 (1.33–3.13)
T3 2.10 (1.36–3.25) 2.06 (1.36–3.13) 3.46 (2.22–5.42)
sPLA2 mass T1 1.00 1.08 (0.69-1.67) 1.69 (1.10–2.59)
T2 1.18 (0.77–1.79) 1.63 (1.07–2.47) 1.81 (1.20–2.74)
T3 1.47 (0.96–2.27) 1.96 (1.30–2.96) 2.39 (1.58–3.61)
Lp-PLA2 activity T1 1.00 1.09 (0.71–1.68) 1.60 (1.04–2.45)
T2 0.95 (0.61–1.47) 1.70 (1.11–2.61) 1.83 (1.19–2.81)
T3 1.13 (0.72–1.77) 1.28 (0.82–1.97) 1.66 (1.08–2.56)
MPO mass T1 1.00 0.91 (0.60–1.39) 1.25 (0.83–1.88)
T2 0.91 (0.60–1.38) 1.12 (0.75–1.68) 1.51 (1.01–2.26)
T3 0.79 (0.51–1.21) 1.50 (1.00–2.25) 1.64 (1.10–2.44)
Lp(a)
sPLA2 activity T1 1.00 0.84 (0.54–1.32) 1.47 (0.96–2.26)
T2 1.16 (0.76–1.79) 1.36 (0.89–2.08) 1.82 (1.20–2.77)
T3 1.42 (0.93–2.17) 2.02 (1.33–3.08) 2.97 (1.93–4.57)
sPLA2 mass T1 1.00 1.18 (0.77–1.82) 1.71 (1.13–2.61)
T2 1.25 (0.83–1.88) 1.51 (1.00–2.29) 1.97 (1.32–2.95)
T3 1.70 (1.11–2.61) 1.72 (1.14–2.60) 2.57 (1.71–3.87)
Lp-PLA2 activity T1 1.00 0.94 (0.61–1.44) 1.73 (1.15–2.61)
T2 1.00 (0.65–1.53) 1.37 (0.91–2.07) 1.94 (1.29–2.90)
T3 1.16 (0.76–1.79) 1.28 (0.83–1.98) 1.53 (1.01–2.32)
MPO mass T1 1.00 0.92 (0.60–1.39) 1.39 (0.93–2.09)
T2 0.88 (0.59–1.31) 1.31 (0.87–1.98) 1.63 (1.11–2.39)
T3 1.03 (0.70–1.54) 1.28 (0.85–1.93) 1.80 (1.20–2.68)
sPLA2 activity
sPLA2 mass T1 1.00 1.40 (0.94–2.09) 1.54 (0.99–2.38)
T2 1.32 (0.87–1.99) 1.64 (1.10–1.44) 1.80 (1.21–2.68)
T3 1.32 (0.83–2.08) 1.56 (1.03–2.35) 2.86 (1.96–4.18)
Lp-PLA2 activity T1 1.00 1.54 (1.03–2.31) 2.68 (1.78–4.02)
T2 1.42 (0.95–2.13) 1.93 (1.31–2.85) 3.52 (2.36–5.25)
T3 1.79 (1.16–2.77) 2.36 (1.58–3.53) 2.79 (1.93–4.03)
MPO mass T1 1.00 1.50 (0.94–2.38) 1.93 (1.24–3.01)
T2 1.39 (0.88–2.22) 1.60 (1.01–2.54) 2.16 (1.36–3.44)
T3 1.30 (0.81–2.06) 1.79 (1.13–2.84) 2.91 (1.82–4.67)
sPLA2 mass
Lp-PLA2 activity T1 1.00 1.90 (1.19–3.04) 2.40 (1.53–3.76)
T2 1.89 (1.20–2.98) 1.90 (1.20–2.99) 2.47 (1.56–3.89)
T3 1.66 (1.04–2.64) 1.85 (1.19–2.90) 2.29 (1.43-3.68)
MPO mass T1 1.00 1.01 (0.67–1.52) 1.74 (1.15–2.63)
T2 1.11 (0.74–1.67) 1.41 (0.94–2.11) 1.52 (1.02–2.29)
T3 1.07 (0.70–1.65) 1.63 (1.09–2.44) 1.80 (1.20–2.69)
Lp-PLA2
MPO mass T1 1.00 1.35 (0.88–2.06) 1.22 (0.79–1.88)
T2 1.04 (0.67–1.61) 1.45 (0.96–2.19) 1.46 (0.94–2.26)
T3 1.54 (1.01–2.33) 1.50 (0.97–2.31) 1.37 (0.89–2.12)
Tertiles for each biomarker are as follows: OxPL/apoB: T1 0 to 1,350, T2 1,351 to 2,249, T32,249; Lp(a): T1 0 to 7.25, T2 7.26 to 11.73,
T311.74; sPLA2 activity: T1 0 to 4.05, T2 4.05 to 4.83, T34.83; sPLA2mass: T1 0 to 6.8, T2 6.8 to 11.2, T311.2; Lp-PLA2 activity:
T10 to44.1, T244.1 to 56.2, T356.2;myeloperoxidasemass; T10 to397, T2397 to726, T3726. The odds ratios are given formodel 1,
which corrected for sex, age, and enrollment time and adjusted for diabetes, smoking, systolic blood pressure, and LDL and HDL cholesterol.
MPO  myeloperoxidase; T  tertile; other abbreviations as in Tables 1 and 2.
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ass and sPLA2 activity appeared additive (Table 3), suggest-
ng that different biological information may be derived from
ach measurement.
For the fatal CAD end point alone, the ORs for risk of
uture CAD for subjects in the highest tertiles for both
xPL/apoB and Lp(a), sPLA2 activity, sPLA2 mass, Lp-
LA2 activity, and myeloperoxidase mass were 2.03 (95%
I: 1.12 to 3.67), 4.56 (95% CI: 1.87 to 11.11), 5.42 (95%
I: 2.20 to 13.39), 1.84 (95% CI: 0.82 to 4.11), and 1.86
95% CI: 0.85 and 4.09), respectively, compared with the
owest tertiles. For subjects in the highest tertiles for both
p(a) and sPLA2 activity, sPLA2 mass, Lp-PLA2 activity,
nd myeloperoxidase mass, the ORs were 4.67 (95% CI:
Figure 1 Odds Ratios for Fatal and Nonfatal CAD Based on
Tertiles of OxPL/apoB or Lp(a) and sPLA2 Activity
Odds ratios for coronary artery disease (CAD) based on tertiles of oxidized
phospholipids on apolipoprotein B-100 (OxPL/apoB) and secretory phospho-
lipase A2 (sPLA2) activity (A) and tertiles of lipoprotein(a) [Lp(a)] and sPLA2
activity (B). The tertile cutoffs for OxPL/apoB are 1,150 relative light units
(RLUs), 1,151 to 2,249 RLUs, and 2,249 RLUs for Lp(a) 7.25, 7.25 to
11.69, and 11.69 mg/dl, and for sPLA2 activity levels 4.05, 4.05 to 4.83,
and 4.83 nmol/min/ml..96 to 11.10), 7.27 (95% CI: 2.99 to 17.68), 1.95 (95% CI: a.89 to 4.26), and 2.83 (95% CI: 1.26 to 6.34), respectively,
ompared with the lowest tertiles.
eceiver-operator characteristic c-index values. To assess
he predictive value of the utility of these biomarkers above
he FRS, receiver-operator characteristic unconditional
-indexes were generated. Table 4 displays the c-index values
f the various biomarkers. The c-index for the FRS was
.584 (95% CI: 0.558 to 0.609), a relatively low value that
eflects the fact that age and sex were already accounted for
s part of the matching design. Adding individual biomar-
ers to the FRS shows that the c-index increased from 0.584
95% CI: 0.558 to 0.609) to 0.618 (95% CI: 0.593 to 0.642),
n progressing order of myeloperoxidase mass, Lp-PLA2
ctivity, OxPL/apoB, high-sensitivity C-reactive protein,
p(a), sPLA2 mass, and sPLA2 activity. Adding biomarkers
o FRS until all biomarkers were present in the model
Figure 2 Odds Ratios for Fatal and Nonfatal CAD
Based on Tertiles of OxPL/apoB and Lp(a)
The tertile cutoffs for OxPL/apoB are 1,150, 1,151 to 2,249, and 2,249
RLUs and 7.25, 7.25 to 11.69, and 11.69 mg/dl for Lp(a). Abbreviations
as in Figure 1.
-Index Values for Area Undereceiver-Op rat Characteristic CurvesTable 4 c-Index V lues for Area UnderReceiver-Operator Characteristic Curves
FRS 0.584 (0.558–0.609)
FRS, MPO 0.586 (0.561–0.612)
FRS, Lp-PLA2 0.587 (0.562–0.613)
FRS, OxPL/apoB 0.597 (0.572–0.623)
FRS, hsCRP 0.605 (0.580–0.630)
FRS, Lp(a) 0.607 (0.582–0.632)
FRS, sPLA2 mass 0.609 (0.584–0.634)
FRS, sPLA2 activity 0.618 (0.593–0.642)
FRS, MPO, Lp-PLA2 0.590 (0.565–0.616)
FRS, MPO, Lp-PLA2, OxPL/apoB 0.603 (0.578–0.628)
FRS, MPO, Lp-PLA2, OxPL/apoB, hsCRP 0.614 (0.590–0.639)
FRS, MPO, Lp-PLA2, OxPL/apoB, hsCRP, Lp(a) 0.625 (0.600–0.649)
FRS, MPO, Lp-PLA2, OxPL/apoB, hsCRP, Lp(a),
sPLA2 mass
0.635 (0.610–0.659)
FRS, MPO, Lp-PLA2, OxPL/apoB, hsCRP, Lp(a),
sPLA2 mass, sPLA2 activity
0.651 (0.627–0.675)
alues are c-index (95% confidence interval).
FRS Framingham Risk Score; hsCRP high-sensitivity C-reactive protein; other abbreviations
s in Tables 1, 2, and 3.
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.558 to 0.609) to 0.651 (95% CI: 0.627 to 0.675 (Table 4,
nline Figure 1). There were no differences in the c-index
alues if a conditional c-index was calculated (data not
hown).
elationship of OxPL/apoB and Lp(a) levels to the
etabolic syndrome. In the overall cohort, the mean
umber of criteria for the metabolic syndrome was 2.5 
.0, and the FRS estimated 10-year risk was 19  11%.
xPL/apoB and Lp(a) levels were not statistically associ-
ted with the number of metabolic syndrome criteria or FRS
stimates (Table 5).
elationship of oxidative biomarkers to FRS. To assess
hether oxidative biomarkers provided additional predictive
alue to the FRS, tertiles of OxPL/apoB, Lp(a), sPLA2
ass, sPLA2 activity, Lp-PLA2 activity, and myeloperoxi-
ase mass were evaluated within each FRS risk estimate
Fig. 3). In the low FRS categories, the OxPL/apoB and
p(a) measures did not provide additional predictive value,
ut sPLA2 mass and activity showed a near tripling of the
R. However, in the high FRS estimates, OxPL/apoB and
p(a) more than doubled the OR for predicting new
ardiovascular events, sPLA2 mass and activity were slightly
ess predictive, and Lp-PLA2 activity and myeloperoxidase
ass did not appear to add any additional discriminative
alue within the FRS risk categories.
The combination of OxPL/apoB and sPLA2 activity was
articularly useful in reflecting risk adjustment among the
RS categories. For example, in the low FRS category,
ompared with the lowest tertiles, the highest tertiles of
xPL/apoB and sPLA2 activity were associated with an
R of 8.48 (95% CI: 2.98 to 24.16; p  0.001), 5.01 (95%
I: 2.28 to 11.41, p  0.001) in the medium FRS category,
nd 14.35 (95% CI: 6.21 to 33.17; p  0.001) in the high
RS category.
iscussion
his case-control study nested within the prospectively
ollowed EPIC-Norfolk cohort demonstrates that elevated
aseline levels of OxPL/apoB and Lp(a) are strongly asso-
iated with an increased risk of fatal and nonfatal CAD
vents. Furthermore, increased levels of phospholipases
nvolved in the breakdown of OxPL, particularly sPLA2
elationship of OxPL/apoB and Lp(a) Levels to the Metabolic SyndTable 5 Relationship of OxPL/apoB and Lp(a) Levels to the Me
Metabolic Sy
0 1 2
OxPL/apoB 3,105 (1,597–4,644) 1,826 (1,313–2,834) 1,819 (1,226–2,83
Lp(a) 11.06 (6.94–27.16) 8.94 (6.60–21.01) 8.61 (6.38–13.81
F
<10%
OxPL/apoB 1,721 (1,273–2,44
Lp(a) 8.03 (6.08–13.14xPL/apoB values are in relative light units (RLU) and Lp(a) in mg/dl and are presented as median (inte
Abbreviations as in Table 1.ctivity and mass, potentiated the risk mediated by either
xPL/apoB or Lp(a). For the first time, this study links
istinct oxidative processes, ranging from oxidative sub-
trates, carriers of OxPL such as Lp(a), and enzymes that
ither generate or degrade oxidized lipids, in the association
f fatal and nonfatal CAD events. Individually these oxida-
ive biomarkers were independent of traditional risk factors
nd the FRS, and collectively they modestly increased the
isk prediction of CAD events, likely because they represent
athophysiologically related but distinct pathways.
OxPL are key components of minimally oxidized LDL,
ully oxidized LDL, apoptotic cells, and atherosclerotic
esions and are important contributors to atherogenesis by
ctivating proinflammatory genes, leading to inflammatory
ascades in the arterial wall. This study provides insights
nto the atherogenicity of OxPL/apoB and Lp(a) and
elated oxidative biomarkers in several novel ways. It dem-
nstrates in a large, prospective nested case-control study
hat OxPL/apoB levels are strongly and independently
ssociated with future risk of fatal and nonfatal CAD
vents. These data confirm the findings from the smaller but
rospective Bruneck study in which elevated baseline levels
f OxPL/apoB levels predicted future risk of all-cause
ortality, myocardial infarction, and stroke (13). Impor-
antly, it also demonstrates for the first time that evaluating
xPL/apoB and Lp(a) together in the same model further
ncreases the OR for CAD events. This suggests that
lthough high Lp(a) levels can be associated with high
xPL/apoB levels in many patients, there may be a diver-
ence of levels in other patients, implying that not all Lp(a)
articles carry the same amount of E06-detectable OxPL.
ne potential explanation influencing this observation may
e the underlying differences in the genetic makeup and
linical presentation of the individuals or patient cohorts in
hese studies. For example, in the Mayo Clinic study (11),
xPL/apoB levels were an independent predictor of
ngiographically determined CAD in patients younger
han 60 years of age, even with Lp(a) in the multivariable
odel. However, in the Bruneck study evaluating carotid
nd femoral atherosclerosis in healthy subjects, OxPL/
poB and Lp(a) provided similar risk prediction (13).
ew insights into the OxPL-Lp(a) relationship were
ecently obtained from the Dallas Heart Study in which
and Framingham Risk Score Estimateslic Syndrome and Framingham Risk Score Estimates
e Parameters
p Trend
Linearity3 4 5
,711 (1,172–2,965) 1,718 (1,314–2,350) 1,652 (1,045–2,241) 0.70
8.63 (6.70–16.87) 9.06 (6.40–16.96) 7.58 (6.00–14.34) 0.40
ham Risk Score Estimates
10%–20% >20%
,827 (1,330–3,099) 1,711 (1,235–2,715) 0.80
8.97 (6.74–15.93) 8.84 (6.53–16.87) 0.20rometabo
ndrom
4) 1
)
raming
2) 1
)rquartile range).
i
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F
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cantly according to race, with the highest levels found in
Figure 3 Relationship of Oxidative Biomarkers and Lp(a) to Fra
Relationship between tertile groups of OxPL/apoB (1,150, 1,151 to 2,249, and
ity (4.05, 4.05 to 4.83, and 4.83 nmol/min/ml [C]), sPLA2 mass (6.80, 6.8
56.23 nmol/min/ml [E]), and myeloperoxidase mass (396.7, 396.7 to 726.3,
group. The Framingham Risk Score was calculated as low risk (10% risk of even
**p  0.001 for comparison of each tertile of the respective biomarkers with the
Lp-PLA2  lipoprotein-associated phospholipase A2; other abbreviations as in Figulacks, followed by whites and then Hispanics (24). eurthermore, OxPL/apoB levels were inversely associ-
ted with apolipoprotein(a) isoform size. Despite differ-
ham Risk Score Estimates
9 RLUs [A]), Lp(a) (7.25, 7.25 to 11.69, and 11.69 mg/dl [B]), sPLA2 activ-
1.29, and 11.19 mg/dl [D]), Lp-PLA2 activity (44.05, 44.05 to 56.23, and
726.3 pmol/l [F]) and future CAD risk within each Framingham Risk Score
r 10 years), moderate risk (10% to 20%), and high risk (20%). *p  0.05 and
t tertile in the low Framingham Risk Score category of each biomarker.ming
2,24
0 to 1
and 
ts ove
lowes
re 1.nces in Lp(a) levels between racial/ethnic groups, a
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mall apolipoprotein(a) isoforms, but not large isoforms,
uggesting that elevated OxPL/apoB levels in the setting
f small apolipoprotein(a) isoforms may be the key
eterminant of CVD risk in this relationship.
This study demonstrates that the association of OxPL/
poB and Lp(a) with CAD was independent of measures of
he metabolic syndrome. Furthermore OxPL/apoB, Lp(a),
nd sPLA2 activity and mass were also independent of other
stablished CVD risk factors and FRS estimates. This was
oted despite the fact that age and sex were already adjusted
or in both groups, and it is possible that these recalibrations
f FRS risk estimates are underestimated. Interestingly,
PLA2 activity and mass significantly increased the predic-
ive value of the low-risk FRS category. On a community-
ide basis, this is a large group of subjects who are generally
ot treated for CVD risk. For this group in particular, these
easures may be useful to further stratify subjects now
ategorized by the FRS as low risk into higher risk catego-
ies, which might affect treatment decisions.
This study links OxPL/apoB and Lp(a) in the association
ith CAD with other clinically relevant oxidative biomarkers
nd particularly with sPLA2 type IIA mass and sPLA2 activity.
he combination of either OxPL/apoB or Lp(a) with sPLA2
ctivity was a particularly strong marker of risk in this study,
articularly for fatal CAD. Elevated levels of sPLA2 type IIA
ass and sPLA2 activity, which encompasses sPLA2 types
IA, V, and X, were previously shown to be independent
redictors of death and new or recurrent myocardial infarction
n healthy subjects and in patients with acute coronary syn-
romes (2,21,25,26). The fact that sPLA2 activity levels have
dditive predictive value for OxPL/apoB and Lp(a) suggests
hat these factors may mediate risk at different points in the
ontinuum of atherogenesis.
We had previously demonstrated in the Bruneck study
13) a similar relationship between OxPL/apoB or Lp(a)
nd Lp-PLA2 activity, with the nearly doubling of the
azard ratio for congestive heart disease. However, in
ontrast to the Bruneck study, a weak association was noted
n EPIC-Norfolk. Differences in methodology (prospective
s. case control) or the size of the study (82 vs. 763 events)
r other factors may explain the disparate findings. Simi-
arly, only a weak potentiation of risk of most of the other
xidative biomarkers measured in this study was noted with
yeloperoxidase.
This is the first analysis of receiver-operator characteristic
-index values of a combination of oxidative biomarkers,
hich were evaluated by adding them to FRS estimates
ndividually and in combination. It must be emphasized
hat c-index values are an imperfect measure and should
ot be used in isolation for clinical risk prediction (27). In
his study, age and sex, which generally contribute
ignificantly to the c-index, were not part of the c-index
ue to the nested case-control methodology. In combi-
ation, adding individual biomarkers consecutively added
o the c-index, ultimately increasing it from 0.584 to p.651, a change similar to recently reported studies of
onoxidative biomarkers (28).
A strong database exists with assays in detecting OxPL
nd oxidized LDL in their association with CVD and CVD
vents (6–8). Additionally, previous studies have evaluated
ther oxidative biomarkers in subjects with congestive heart
isease, such as urinary isoprostanes (29), serum malondi-
ldehyde levels measured as thiobarbituric reactive sub-
tances (30), and glutathione redox state (31). In a recent study
32), the relationship of OxPL/apoB, Lp(a), and immunoglob-
lin G and M autoantibodies to malondialdehyde-LDL,
mmunoglobulin G and M apoB- immune complexes, Lp-
LA2 activity, oxidized LDL by the Mercodia assay, and
rinary F2 isoprostanes were evaluated in 160 subjects with
ypercholesterolemia treated with various doses of different
tatins. Remarkably, the baseline levels and the response to
arious statins on plasma levels of the biomarkers were quite
ariable, and no strong relationships were noted among
hese biomarkers. Thus, even though these biomarkers are
onceptually related, they did not seem to reflect the same
athophysiology. The overall reported experience of many
f these markers in predicting cardiovascular events is
imited at this stage, and certain limitations exist. For
xample, urinary isoprostanes correlate with cardiovascular
isk factors but are not widely available and require signif-
cant expertise and instrumentation to measure accurately.
alondialdehyde measures can be nonspecific because they
re generated by sources other than lipid hydroperoxides
uch as platelets, glucose, bilirubin, and amino acids. How-
ver, they were predictive of new events in the PREVENT
Prospective Randomized Evaluation of the Vascular Effects
f Norvasc Trial) study (30). Glutathione redox state is a
romising oxidative marker, and elevated levels predict
ubclinical atherosclerosis in unselected populations, but
linical outcomes data are awaited to assess their clinical
redictive value (31).
Previous studies have not generally incorporated modifi-
ble biomarkers in their multiple biomarker approaches to
mprove risk stratification for CVDs. Even though the
resent data should not be interpreted as implying a clinical
enefit from reduction in these biomarkers, it is interesting
o note that most of these oxidative biomarkers can be
odified by therapeutic interventions such as statins and
ther CVD therapies (33). In addition, sPLA2 and Lp-
LA2 inhibitors are currently undergoing evaluation in
linical trials to assess whether they reduce the incidence of
VD events (34,35). Thus, if confirmed by prospective
herapeutic studies, these results may have important impli-
ations for patient selection for treatment with approved or
merging CVD therapies.
tudy limitations. The c-index values in this study were
elatively low due to the fact that controls were matched to
ases by sex and age, thus removing a substantial amount of
heir discriminatory ability. The nested case-control design
nly allowed us to assess the relative but not absolute risk
rediction of oxidative biomarkers.
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xidation-specific biomarkers are strongly associated with
AD events and can be a useful adjunct to traditional risk
actors or FRS in risk prediction of future CAD in initially
ealthy subjects.
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